Patents by Inventor Frank Herting

Frank Herting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR
    Publication number: 20240139192
    Abstract: The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.
    Type: Application
    Filed: December 8, 2023
    Publication date: May 2, 2024
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jan ECKMANN, Thomas FRIESS, Frank HERTING, Yusuke IDE, Hiroshi TANAKA, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20230212277
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 6, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Antibody fab and Fc variants
    Patent number: 11525007
    Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: December 13, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Frank Herting, Sylvia Herter, Christian Klein, Ekkehard Moessner, Tilman Schlothauer
  • Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1
    Patent number: 11512133
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 29, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Frank Herting, Sabine Hoves, Carola Ries, Katharina Wartha
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20210095013
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 5, 2020
    Publication date: April 1, 2021
    Applicant: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20200392234
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: February 6, 2020
    Publication date: December 17, 2020
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frank HERTING, Sabine HOVES, Carola RIES, Katharina WARTHA
  • Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
    Patent number: 10683345
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 16, 2020
    Assignee: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • ANTIBODY FAB AND FC VARIANTS
    Publication number: 20190106502
    Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.
    Type: Application
    Filed: August 21, 2018
    Publication date: April 11, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Frank Herting, Sylvia Herter, Christian Klein, Ekkehard Moessner, Tilman Schlothauer
  • ANTIBODY FC AND FAB VARIANTS
    Publication number: 20190092872
    Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having reduced effector function and altered ability to mediate cell signaling activity by a target antigen. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.
    Type: Application
    Filed: August 21, 2018
    Publication date: March 28, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Frank Herting, Sylvia Herter, Christian Klein, Ekkehard Moessner, Tilman Schlothauer
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20180346581
    Abstract: The present invention relates to the combination therapy of specific antibodies which human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: April 19, 2018
    Publication date: December 6, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frank HERTING, Sabine HOVES, Carola RIES, Katharina WARTHA
  • COMBINATION THERAPY OF ANTIBODY BINDING TO ANGIOPOIETIN 2 WITH ANTIBODY BINDING TO PROGRAMMED DEATH LIGAND 1
    Publication number: 20180155431
    Abstract: The present invention relates to a combination therapy of an antibody specifically binding to Angiopoietin 2 (ANG-2), and an antibody specifically binding to VEGF with an antibody specifically binding to programmed death ligand 1 (PD-L1).
    Type: Application
    Filed: October 19, 2017
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Frank Herting, Hans-Joachim Mueller
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20170260265
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Applicant: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
    Patent number: 9695233
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: July 4, 2017
    Assignee: ROCHE GLYCART AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20170051065
    Abstract: The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: July 29, 2016
    Publication date: February 23, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frank HERTING, Sabine HOVES, Carola RIES, Katharina WARTHA
  • Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor
    Publication number: 20160347852
    Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a Bcl-2 inhibitor and a MDM2 inhibitor.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 1, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Frank Herting, Markus Dangl
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE
    Publication number: 20160166688
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine.
    Type: Application
    Filed: May 8, 2014
    Publication date: June 16, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: FRANK HERTING, CHRISTIAN KLEIN
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF
    Publication number: 20160017050
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 21, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: Frank Herting, Christian Klein
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC)
    Publication number: 20160000911
    Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
    Type: Application
    Filed: June 5, 2014
    Publication date: January 7, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: CHARLES DUMONTET, THOMAS FRIESS, FRANK HERTING, CHRISTIAN KLEIN, PABLO UMANA
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE
    Publication number: 20150274834
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 1, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: Martin Dreyling, Daniel Alexander Heinrich, Frank Herting, Christian Klein
  • COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR
    Publication number: 20150265703
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: Frank Herting, Christian Klein